The shortage of blood donor dogs in veterinary emergencies can lead to blood transfusions between animals whose blood type has not been identified. The antibody profile serves as a warning sign for animals that require a second blood transfusion, which is only advisable from compatible donor dogs. This article focuses on the determination of anti-DEA 1 antibodies using the flow cytometry technique in dogs that have undergone a transfusion using DEA 1-positive blood, compared to results obtained from crossmatching. Blood from 18 DEA 1-positive donors ranked according to the chromatographic technique was used to transfuse thirty-three animals with unknown blood types and which demonstrated negative crossmatching to donors. On post-transfusion days 7, 14, 21 and 28, 45% and 27% of the animals tested positive for the anti-DEA 1 antibody, through crossmatching and flow cytometry, respectively. Detecting antibodies using the flow cytometric technique has high specificity and sensitivity, while crossmatching methods are highly sensitive but manifest low specificity. Following the blood transfusion, animals that did not present as positive through crossmatching or flow cytometry were considered different from all other DEA 1-positive blood groups. Keywords: Alloantibodies. Canine antibodies. DEA 1. Blood transfusion in dogs.
Introduction
Although blood transfusions can save lives, they also present risks and do not guarantee absolute security for transfused animals. Immune-mediated reactions may be caused by antibody interactions with antigens present in allogeneic cells or with proteins present in plasma (DAVIDOW, 2013; KOHN et al., 2014) . Alloimmunization in dogs occurs when there is a sensitization of the immune system by other antigens.
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Alloantibodies against dog erythrocyte antigen (DEA) 1 (1.1, 1.2), 3, 5, 7 and Dal occur after contact with a receiver that does not have this blood type (BLAIS et al., 2007; KESSLER et al., 2010) . These reactions have been described in dogs but have not been characterized individually, due to limited viability of classification procedures and lack of comparative studies between different blood group systems and reagents (BLOIS et al., 2013; ACIERNO et al., 2014) . According to Giger (2014) , the strong antigenicity of DEA 1 means that donor blood typing is recommended. Canine blood typing is based on serologic identification through agglutination reactions, although serum from sensitized dogs has been used for typing; however, these polyvalent alloantibodies vary from batch to batch. In theory, the ideal blood donor is a dog that is negative for DEA 1 (1.1, 1.2), 3, 5 and 7. However, due to the high population frequency of DEA 1, that includes 1.1 and 1.2, sampling to obtain blood from positive donors reduces the maintenance of the blood supply. Frequently, no assessment of cross-reactivity takes place to determine the occurrence of blood incompatibility. We note that cross-reactivity does not impede the sensitization of receivers (CALLAN et al., 1995; TOCCI; EWING, 2009 ).
Flow cytometry is widely applied in hematology, not only to identify cell phenotypes but also to detect antibodies (NAKAGE et al., 2005; RAMOS-VARA et al., 2011) . Ata et al. (2012) reported an anti-A2 antibody in humans that received incompatible renal transplant. This method has also been used in veterinary hematology to detect DEA 1 from antibodies using this methodology. Lucidi et al. (2011) researched DEA 1 in platelets but did not identify it while Polak et al. (2015) used the technique to research DEA 1 in erythrocytes using this methodology.
Since research into post-transfusion alloantibodies is limited, the present investigation was performed to identify the presence of antibodies anti-DEA 1 in dogs undergoing blood transfusions and compare results obtained from flow cytometry assay with those from crossmatching techniques. This study also investigated the progression of the production of antibodies against DEA 1 in dogs who received red blood cell products.
Materials and Methods
The project was approved by the Ethics Committee on Animal Use of the Institute of Health Sciences/Federal University of Bahia (Protocol No. 048/2013) . The owners of the study animals were informed of the work methodology and signed the Instrument of Consent.
Eighteen applicant donor dogs whose laboratory blood count tests and biochemical analyses were within the normal range for the species were selected. The dogs also tested negative for the following diseases: ehrlichiosis, babesiosis, heartworm and leishmaniasis. Donor dog blood typing was performed using the chromatographic technique with the Alvedia® (Limonest, France) commercial kit, in line with the manufacturer-recommended method.
The donor group consisted of eight males and ten female dogs of various breeds, including eight Afghan Hounds, one Doberman, one Fila Brasileiro, two Labradors and six Belgian Malinois Shepherds, with an average age of 4.8 years and an average weight of 34.7 kg. Selected bags of fresh whole blood were processed no more than two days following collection to prevent hemolytic storage lesion, in line with Duggan (2011) and McDevitt et al. (2011) .
The group of recipient animals was composed of 33 dogs recommended for blood transfusion, from a variety of breeds (five Rottweilers, four Yorkshire terriers, one Chow, one Doberman Pinscher, one Schnauzer, eight Poodles, one Maltese, one Golden Retriever, one Akita, two Pit Bulls, one Labrador Retriever and seven mongrels), 14 males and 19 females, with an average age of 7.4 years.
Whole blood from DEA 1-classified samples was used for transfusion to the receiver group following compatibility evaluation using crossmatching, as described by Lanevschi and Wardrop (2001) . The crossmatching results were based on the degree of agglutinated erythrocytes, classified according to Gibson (2007) with intensity varying from zero to four crosses. Sheep polyclonal anti-dog IgG AA132F FITC AbD Serotec® (Bio-Rad, Hercules, CA, USA) was used for the flow cytometry, which was performed on a Becton Dickinson FACSCalibur™ interfaced with a Power Macintosh computer (Apple, Salvador, BA, Brazil, performed at the Immunology Laboratory of the Federal University of Bahia) with instrument-specific computer software (BD CellQuest Pro™ software, Becton, Dickinson and Company). The steps were as follows:
• identification of anti-DEA 1 antibodies in the receivers via crossmatching assay on posttransfusion days 7, 14, 21 and 28; • detection of anti-DEA 1 antibodies in the receivers through flow cytometry on post-transfusion days 7, 14, 21 and 28; • comparing the antibody screening results from the flow cytometry with those from the crossmatching performed on post-transfusion days 7, 14, 21 and 28.
The search for anti-DEA 1 antibodies followed the method used by Lucidi et al. (2011) , with adjustments arising from the use of the erythrocyte antigen, since the original protocol used platelets. We maintained the test cell control for the detection of anti-DEA 1 antibodies using the same red blood cells from a DEA 1-positive dog blood donor. The negative control serum was obtained from an animal known to be DEA 1-negative, and the same sample was used throughout the study. The anti-DEA 1 antibodypositive serum obtained from the receiver animal's blood was added to the total polyclonal FITC-conjugated IgG. The cut-off point was based on a comparison of the negative results from the crossmatching tests with those from the flow cytometry.
The experimental procedure consisted of centrifuging 2 ml of EDTA whole blood with 6 million DEA 1-positive erythrocytes per dL at 2200 x g for 3 minutes. The plasma was discarded, and the packed red blood cells were resuspended in the same saline volume. Two µL of this concentrate was then mixed with 998 µL of saline and homogenized by vortexing the solution. The test and negative control serum samples, each containing 50 µL, were incubated at 56 °C for 10 minutes and then incubated with 40 µL of the diluted erythrocyte solution at room temperature for 30 minutes. Serum samples with erythrocyte suspension were washed in saline three times by centrifugation at 2200 x g for 3 minutes. Sera were added to the vials for testing and to the negative control, and the samples were incubated with 3 μL of anti-dog IgG antibody at room temperature, protected from light, for 30 minutes. The samples were then washed in saline at 2200 x g for 3 minutes. The sera in all vials were resuspended twice in 300 µL of saline and, finally, cytometry readings were made.
Statistical analyses were used to assess the results of the crossmatching and cytometry analyses of DEA 1 antibodies.
The mean and standard deviations of the 33 individuals were surveyed over the four-week period. The comparison between flow cytometry was performed using ANOVA with the post-hoc Tukey test. Since crossmatching is an ordinal variable, the comparisons were analyzed using the Chi square test. The analyses were considered statistically significant at p < 0.05. All analyses were performed using the Statistical Package for Social Sciences (SPSS), version 17.0. The data were graphically displayed using Prism 5 software, version 5.01.
Results
A total of 9 (27%) out of the 33 tested dogs were positive for the presence of anti-DEA 1 antibodies using flow cytometry, while 15 animals (45%) from the same group of dogs tested positive through crossmatching with DEA 1-positive blood samples.
Differences were observed in the animals in varied crossmatching intensity in the four weeks following transfusion (Table 1) . Table 2 shows the number of blood receivers, with the number of crosses representing crossmatching intensity over the four study weeks.
The flow cytometry analysis for individuals who evidenced crossmatching resulted in negative values ranging from 4 to 14.6 in fluorescence intensity. Samples that obtained values above 14.6 were considered positive; these values ranged from 15 to 538.99. The average number of anti-DEA 1 antibodies obtained in the first week was 6.714 ± 2.436, rising to 9.431 ± 1.129 in the second week. In the third week, the average increased to 16.200 ± 23.70, while the highest value in the fourth week was 38.570 ± 96.98 (Table 3) . However, significant differences were only observed between the first and fourth (p = 0.026), and the second and fourth weeks (p = 0.038). Figures 1 and 2 show the results of the crossmatching and flow cytometry assays by columns, as seen below. 
Discussion
The blood donor group represented type DEA 1-positive individuals. In the literature, the DEA 1 results for the typing parameters of the canine population in Brazil are extremely high (NOVAIS et al., 1999; ESTEVES et al., 2011; SOUZA et al., 2014) . Acierno et al. (2014) , observed the prevalence of DEA 1 among the world's dog population varies between 10 and 100% and is more prevalent within racial groups or due to close inbreeding, compared to genetically mixed populations, resulting in a worldwide estimate of 50%. In our group of donor animals, we observed that all the dogs from the Belgian Malinois Shepherd and test demonstrated high sensitivity. However, the crossmatching test may provide false positives, thus rendering inaccurate any comparison between the two approaches. As described in the literature, there is no gold standard technique for blood typing. Flow cytometry was used by Acierno et al. (2014) and Polak et al. (2015) because of its high specificity and the possibility of detecting alloantibodies. The data confirm that flow cytometry is indeed highly specific for the detection of alloantibodies. However, in practice, this technique is of limited access, due to its high cost, while crossmatching remains highly accessible in clinical practice, due to its low cost. Despite its specificity limitations, crossmatching remains a viable choice for pre-transfusion testing. Blood transfusion is a complex and varied cell therapy, and the most common exposure route for a high concentration of antigens (ZIMRING, 2013) . Its effects generate direct alloimmunization, which is the target of the antibodies in this study. It is not yet clear whether weak DEA 1-positive dogs can trigger an alloantibody response like the response detected in strong DEA 1-positive dogs (ACIERNO et al., 2014) . To standardize the technique, we obtained samples of cells with the antigen at different DEA 1 intensities. Our flow cytometry survey used polyclonal (Serotec) sheep anti-dog antibodies, which were inherently variable and had multiple targets. Moreover, their agglutination reactions appeared to depend on antiserum concentration (ACIERNO et al., 2014; POLAK et al., 2015) . The intensity of each serum sample we tested was dependent on donor DEA 1, which ranged from slightly to strongly positive. Each sample therefore had a distinct positive value , despite varying degrees of intensity.
Conclusions
The detection of antibodies and the evidence of crossmatching demonstrate that the flow cytometry technique has high specificity and sensitivity.
Animals that did not show positivity in the crossmatching and flow cytometry tests following blood transfusion were considered different from all other DEA 1-positive blood groups.
Afghan Hound breeds were type DEA 1. This finding demonstrated that the racial factor was an autosomal dominant trait, as reported by Iazbik et al. (2010) .
Autoagglutination was observed in some patients during the crossmatching tests. According to Callan et al. (1995) , incompatibility reactions in a patient with DEA 1-negative erythrocytes suggest the existence of naturally occurring alloantibodies against the DEA 3, DEA 5 and DEA 7 types, as well as the DEA 1, representing a high frequency of antigenicity. In the flow cytometry study, the test sera were incubated at 56 °C to deactivate the complement system, which, given the observed interference from agglutination (LUCIDI et al., 2011) , optimized the technique. In this study, we observed that the positivity in the crossmatching test was markedly progressive from the second to the fourth week, while there was a reduction in the cross parameter in some individuals during the fourth week. In subjects with a positive flow cytometry test, growth was evidenced numerically following the first week and positive progression continued until the fourth week, thereby confirming the technique's high specificity. Some individuals were crossmatching-positive but flow cytometry-negative, which suggested that they were individuals with alloantibodies for DEA 3, 5 and 7 or with autoantibodies and the auto agglutination typical of autoimmune hemolytic anemia, as mentioned by Blois et al. (2013) .
As noted, only nine (27%) of the animals evaluated over the four weeks demonstrated positivity to the DEA 1 antigen in the flow cytometry, whereas fifteen (45%) animals were positive in the crossmatching tests. Of these fifteen positive animals, seven were negative in the flow cytometry test. These results suggest that other erythrocyte antibodies were possibly involved, since other DEA types might have been present but were not identified in the study. Of the nine animals that were positive in the flow cytometry, only one was negative in crossmatching. This animal only demonstrated mild positivity (numerical fluorescence 20 for a cut-off of 14.7) in the third week of the study. This result demonstrates that crossmatching has a semi-quantitative nature and agglutination may not therefore be noticeable for a low antibody titer. All the animals who presented with higher fluorescence demonstrated positivity in the crossmatching test.
These findings highlight a relationship between the two techniques, thus: flow cytometry proved to be a high specificity technique, whereas the crossmatching
